ADC Therapeutics SA (ADCT)
NYSE: ADCT · IEX Real-Time Price · USD
1.66
+0.07 (4.40%)
Dec 29, 2023, 4:00 PM EST - Market closed
ADC Therapeutics Stock Forecast
Stock Price Forecast
According to 5 stock analysts, the average 12-month stock price forecast for ADCT stock stock is $4.20, which predicts an increase of 153.01%. The lowest target is $2.00 and the highest is $6.00. On average, analysts rate ADCT stock stock as a hold.
Analyst Consensus: Hold
* Price targets were last updated on Nov 20, 2023.
Analyst Ratings
The average analyst rating for ADCT stock from 7 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 3 | 3 | 3 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $3 | Strong Buy | Maintains | $12 → $3 | +80.72% | Nov 20, 2023 |
| TD Cowen | TD Cowen | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 9, 2023 |
| RBC Capital | RBC Capital | Buy Maintains $7 → $6 | Buy | Maintains | $7 → $6 | +261.45% | Nov 8, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +622.89% | Sep 19, 2023 |
| RBC Capital | RBC Capital | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +381.93% | Sep 12, 2023 |
Financial Forecast
Revenue This Year
69.37M
from 209.91M
Decreased by -66.95%
Revenue Next Year
80.80M
from 69.37M
Increased by 16.47%
EPS This Year
-2.39
from -1.99
EPS Next Year
-1.69
from -2.39
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | 74.0M | 89.8M | 117.0M | 233.5M | 304.7M | 407.0M |
| Avg | 69.4M | 80.8M | 99.3M | 175.5M | 247.8M | 331.0M |
| Low | 62.3M | 72.1M | 85.3M | 134.2M | 197.3M | 236.5M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | -64.8% | 29.4% | 44.8% | 135.2% | 73.6% | 64.2% |
| Avg | -67.0% | 16.5% | 22.9% | 76.7% | 41.2% | 33.5% |
| Low | -70.3% | 4.0% | 5.5% | 35.1% | 12.4% | -4.6% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | -2.17 | -0.68 | -0.38 |
| Avg | -2.39 | -1.69 | -1.38 |
| Low | -2.48 | -2.16 | -1.74 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.